Dasatinib reverses Cancer-associated Fibroblasts (CAFs) from primary Lung Carcinomas to a Phenotype comparable to that of normal Fibroblasts
- Silke Haubeiss†1,
- Jens O Schmid†1,
- Thomas E Mürdter1,
- Maike Sonnenberg1,
- Godehard Friedel2,
- Heiko van der Kuip1Email author and
- Walter E Aulitzky3
© Haubeiss et al; licensee BioMed Central Ltd. 2010
Received: 12 January 2010
Accepted: 27 June 2010
Published: 27 June 2010
Cancer associated fibroblasts (CAFs) play a critical role for growth, invasion, and metastasis of cancer. Therefore, targeting CAFs with small molecule inhibitors may be an attractive anti-tumor strategy. The current study aims to identify small molecule kinase inhibitors affecting CAF's growth and to characterize the biological effects of active compounds on primary CAFs from lung cancer. We screened two individual CAF strains for their sensitivity to a panel of 160 kinase inhibitors. Five kinase inhibitors were identified inhibiting more than 50% of the growth of both cell lines. Three of them were inhibitors of PDGFR at nanomolar concentrations. Therefore, we further tested the FDA approved PDGFR inhibitors Dasatinib, Nilotinib, Sorafenib, and Imatinib. All 37 CAF strains investigated were highly sensitive to Dasatinib at clinically relevant concentrations. Imatinib was slightly less effective, whereas the inhibitory effects of Nilotinib and Sorafenib were significantly less pronounced.
We investigated the effect of Dasatinib on the CAF transcriptome by microarray analysis of 9 individual CAF strains. 492 genes were identified whose expression was changed at least twofold. 104 of these encoded cell cycle related proteins with 97 of them being downregulated by Dasatinib. The majority of regulated genes, however, were of diverse biological functions not directly related to proliferation. We compared this Dasatinib expression signature to previously described differential signatures of normal tissue associated fibroblasts (NAFs) and CAFs and to a signature of fibroblast serum response. There was a significant overlap between genes regulated by Dasatinib and serum repression genes. More importantly, of the 313 genes downregulated by Dasatinib 64 were also reduced in NAFs compared to CAFs. Furthermore, 26 of 179 genes identified as upregulated by Dasatinib were also found to be elevated in NAFs compared to CAFs. These data demonstrate that Dasatinib partially reverses the phenotype of CAFs to a normal fibroblast like phenotype. This is further supported by the finding that incubation of tumor cells with conditioned medium from CAFs pre-incubated with Dasatinib significantly reduced tumor cell proliferation, suggesting that Dasatinib partially reverses the CAF mediated tumor promoting effect. Therefore, targeting CAFs with Dasatinib represents a promising therapeutic principle.
The tumor microenvironment or "stroma" actively participates in tumorigenesis, tumor progression, and metastasis. Within the tumor stroma, CAFs are of outstanding importance. CAFs are the primary cell type that produces ECM and thereby determines dynamics of the tumor .
CAFs show a molecular and functional phenotype that is different from NAFs. It has been early recognized by pathologists that in many tumors stroma is characterized by an increased fibroblast proliferation . CAFs also secrete a variety of growth factors and proteinases facilitating tumor growth and invasion [3–5]. The protective and supportive effects of CAFs on tumor cells strongly support the concept that CAFs represent an attractive target for anticancer therapy. The activity of a plethora of kinases is involved in signalling pathways important for the tumor promoting activities of CAFs including receptors for PDGF and TGFβ and corresponding downstream signal transducers . Therefore, we investigated the potency of kinase inhibitors to block CAF activities.
As a next step, we studied the effects of four FDA approved inhibitors Dasatinib, Imatinib, Nilotinib, and Sorafenib, which all target PDGFR in vitro, in a panel of CAF strains from individual lung cancer patients. All four inhibitors blocked CAF growth whereas the EGFR inhibitor Erlotinib, which was used in control experiments, was inactive at clinically relevant concentrations (Figure 1B). However, despite the fact that Dasatinib, Imatinib, Nilotinib, and Sorafenib inhibit PDGFR with comparable IC50 values ranging from 28 nM - 80 nM [15–17], their effects on proliferation and/or viability of CAF strains from lung carcinomas in vitro were remarkably different. Dasatinib was highly efficient in reducing CAF growth already at concentrations below 100 nM (Figure 1B, left panel) whereas approximately 10fold higher inhibitor concentrations were required to achieve a comparable growth reduction by Imatinib, Nilotinib, and Sorafenib (Figure 1B, left panel). The most likely explanation for the diverging biological activities of these PDGFR-inhibitors is the different spectrum of kinases targeted in addition to PDGFR. In contrast to Imatinib, Nilotinib, and Sorafenib, Dasatinib targets a variety of other kinases such as Src kinases, TEC kinases, MAP kinases and others . Combined inhibition of PDGFR together with blocking of intracellular signalling cascades may be more effective than inhibition of PDGFR alone.
Highly different plasma concentrations are achieved in pharmacokinetic studies with Imatinib, Dasatinib, Nilotinib, and Sorafenib [19–22]. To estimate whether the differing in vitro activity of these compounds can also be expected after in vivo exposure we compared inhibitor concentrations corresponding to Cmax values observed in clinical studies. All CAFs responded to Dasatinib at a concentration of 0.11 μM with a reduction of cell growth by 36.4 ± 1.2% (mean ± SEM). Imatinib was slightly less effective (31.5 ± 1.8% at 5.3 μM), whereas the inhibitory effects of Nilotinib and Sorafenib were significantly less pronounced with a reduction of cell growth by 20.5 ± 2.4% and 16.3 ± 1.2%, respectively (Figure 1B). We then studied the mechanism of action of the most effective compounds Dasatinib and Imatinib. Both molecules primarily reduced the fraction of S phase cells as indicated by a significant reduction of DNA synthesis. The effect of Dasatinib on inhibition of proliferation was more pronounced than that of Imatinib (74.5 ± 5.9% versus 35.8 ± 7.5%; Figure 1C). No induction of cell death was seen under these conditions (Figure 1C). Moreover, Dasatinib did not induce senescence in CAFs as β-galactosidase staining was not evident in Dasatinib treated CAFs (Figure 1D). This is further supported by the finding that the Dasatinib-induced proliferation stop is reversible since cells were able to re-enter the cell cycle, synthesize DNA, and proliferate after removal of Dasatinib (Figure 1E). Therefore, Dasatinib represents a highly active compound to block proliferation in CAFs.
However, many genes of the Dasatinib response signature are not overlapping with the serum-repressed pattern. This observation supports the view that Dasatinib induces more than a quiescence-like phenotype in fibroblasts. We therefore compared the Dasatinib response signature to the published differential expression pattern of NAFs and CAFs from breast cancer cases . 64 of the genes found to be downregulated by Dasatinib were also lower expressed in NAFs compared to CAFs, while only 8 genes should be expected by chance alone (p < 10-30; Fisher's exact test). Furthermore, 26 genes were upregulated in CAFs treated with Dasatinib and also in NAFs (4 genes by chance alone; p < 10-11) (Figure 3B; Additional file 6, Table S5). We selected 6 genes from the 90 genes in the overlap for validation by qRT-PCR (Additional file 1, Material and Methods). Two of them were overexpressed (PDGFR and SVEP1). The expression of both could be confirmed to be significantly higher in Dasatinib treated CAFs by qRT-PCR. Four genes downregulated by Dasatinib and lower expressed in NAFs (MMP1, MKI67, TTK, and FOXM1) were confirmed to be reduced by qRT-PCR, reaching significance for MMP1, TTK and FOXM1 (Additional file 7, Figure S1).
In conclusion, our data demonstrate that Dasatinib treatment partially reverses the CAF phenotype in fibroblasts from lung cancer tissues. More importantly, treatment of CAFs with Dasatinib reduces their ability to promote tumor proliferation in vitro. Treatment of lung cancer with Dasatinib may therefore be a promising strategy to enhance the efficacy of conventional therapy.
List of abbreviations
breast cancer susceptibility gene 1/2
cancer associated fibroblast
cell division cycle 20
cycline dependent kinase 2
crystallin, alpha B
E2F transcriptionfactor 7
epithelial growth factor receptor
forkhead box M1
melanoma cell adhesion molecule
antigen identified by monoclonal antibody Ki-67
matrix metallopeptidase 1
mammalian target of rapamycin
normal tissue associated fibroblast
platelet derived growth factor
platelet derived growth factor receptor
pyruvate dehydrogenase kinase 1
protein kinase C/protein kinase A
receptor tyrosine kinase-like orphan receptor 1
sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1
TTK protein kinase
X-ray repair complementing 2.
This work was supported by the Robert-Bosch-Foundation (O2B and 11.5.8000.0083.0).
We are grateful to Kerstin Willecke and Tabea Peußer for technical assistance. We also thank Stephan Winter for assistance with statistical analysis and the staff of the Microarray Facility Tübingen for support.
- Micke P, Ostman A: Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets. 2005, 9: 1217-1233. 10.1517/14728126.96.36.1997View ArticlePubMedGoogle Scholar
- Willis R: Pathology of tumors. 1960, 130-140. Butterworth, London,Google Scholar
- Micke P, Ostman A: Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. Lung Cancer. 2004, 45 (Suppl 2): S163-175. 10.1016/j.lungcan.2004.07.977View ArticlePubMedGoogle Scholar
- Tlsty TD, Hein PW: Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev. 2001, 11: 54-59. 10.1016/S0959-437X(00)00156-8View ArticlePubMedGoogle Scholar
- Orimo A, Weinberg RA: Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle. 2006, 5: 1597-1601.View ArticlePubMedGoogle Scholar
- Shao ZM, Nguyen M, Barsky SH: Human breast carcinoma desmoplasia is PDGF initiated. Oncogene. 2000, 19: 4337-4345. 10.1038/sj.onc.1203785View ArticlePubMedGoogle Scholar
- Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ: Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol. 2006, 169: 2054-2065. 10.2353/ajpath.2006.060653PubMed CentralView ArticlePubMedGoogle Scholar
- Gioni V, Karampinas T, Voutsinas G, Roussidis AE, Papadopoulos S, Karamanos NK, Kletsas D: Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts. Mol Cancer Res. 2008, 6: 706-714. 10.1158/1541-7786.MCR-07-0355View ArticlePubMedGoogle Scholar
- Pietras K, Pahler J, Bergers G, Hanahan D: Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 2008, 5: e19- 10.1371/journal.pmed.0050019PubMed CentralView ArticlePubMedGoogle Scholar
- Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, Fidler IJ: Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res. 2003, 9: 6534-6544.PubMedGoogle Scholar
- Baranowska-Kortylewicz J, Abe M, Pietras K, Kortylewicz ZP, Kurizaki T, Nearman J, Paulsson J, Mosley RL, Enke CA, Ostman A: Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. Cancer Res. 2005, 65: 7824-7831.PubMed CentralPubMedGoogle Scholar
- Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006, 354: 2542-2551. 10.1056/NEJMoa055104View ArticlePubMedGoogle Scholar
- Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006, 354: 2531-2541. 10.1056/NEJMoa055229View ArticlePubMedGoogle Scholar
- Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jüngel A, Zwerina J, Gay S, Schett G, Distler O, Distler JH: Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008, 22: 2214-2222. 10.1096/fj.07-105627View ArticlePubMedGoogle Scholar
- Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005, 7: 129-141. 10.1016/j.ccr.2005.01.007View ArticlePubMedGoogle Scholar
- Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004, 47: 6658-6661. 10.1021/jm049486aView ArticlePubMedGoogle Scholar
- Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006, 5: 835-844. 10.1038/nrd2130View ArticlePubMedGoogle Scholar
- Hantschel O, Rix U, Superti-Furga G: Target spectrum of the Bcr-Abl inhibitors imatinib, nilotinib and dasatinib. Leukemia and Lymphoma. 2008, 49: 615-619. 10.1080/10428190801896103View ArticlePubMedGoogle Scholar
- Peng B, Lloyd P, Schran H: Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005, 44: 879-894. 10.2165/00003088-200544090-00001View ArticlePubMedGoogle Scholar
- Wang X, Hochhaus A, Kantaijan HM, Agrawal S, Roy A, Pfister M, Chen T, Bleickardt E, Nicaise C, Shah N: Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML) [abstract]. J Clin Oncol. 2008, 26: s3590-10.1200/JCO.2008.16.0622.View ArticleGoogle Scholar
- Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD: Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007, 7: 345-356. 10.1038/nrc2126View ArticlePubMedGoogle Scholar
- Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, Mukai H, Tahara M, Nakajima H, Nakajima K: Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci. 2008, 99: 1492-1498. 10.1111/j.1349-7006.2008.00837.xView ArticlePubMedGoogle Scholar
- Coller HA, Sang L, Roberts JM: A new description of cellular quiescence. PLoS Biol. 2006, 4: e83- 10.1371/journal.pbio.0040083PubMed CentralView ArticlePubMedGoogle Scholar
- Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO: Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004, 2: 0206-0214. 10.1371/journal.pbio.0020206.View ArticleGoogle Scholar
- Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA. 2005, 102: 3738-3743. 10.1073/pnas.0409462102PubMed CentralView ArticlePubMedGoogle Scholar
- Sadlonova A, Bowe DB, Novak Z, Mukherjee S, Duncan VE, Page GP, Frost AR: Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts. Cancer Microenviron. 2009, 2: 9-21. 10.1007/s12307-008-0017-0PubMed CentralView ArticlePubMedGoogle Scholar
- Sonnenberg M, van der Kuip H, Haubeis S, Fritz P, Schroth W, Friedel G, Simon W, Mürdter TE, Aulitzky WE: Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer. 2008, 8: 364- 10.1186/1471-2407-8-364PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.